The Effect of Duloxetine on Interoceptive Awareness

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

36 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study focuses on possible mechanism mediating duloxetine effects on painful physical symptoms in patients suffering from MDD. Our hypothesis is based on the assump¬tion of dual impairment of the somatosensory system in these patients. Hypalgesia to phasic experimental pain may be due to diminished spinal and brainstem transmission. Hyperalgesia may be at¬tributed to increased interoceptive perception (somatic complaints, especially those consist¬ing in pain) due to sensitisation or lack of inhibition of the interceptive perception. These ef¬fects seem to be mediated by specific brain regions (e.g. the right insula). The investigators intent to test if duloxetine effects on these somatic complaints, especially pain complaints are due to a nor¬malization of these interceptive alterations which have been reported to be associated with depressive symptoms. The investigators hypothesize that treatment with duloxetine will normalize "patho¬logical" activation patterns (as assessed by fMRI) associated with increased interoceptive perception.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and female (female are enrolled only under the condition of proof of using a safe and medially accepted contraceptive. According to the "Note for guidance on non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals" (CPMP/ICH/286/95, modification) contraceptives with a pearl-index\<1% are considered safe and effective. Among these only hormonal contraceptives, micro-pill and tubal ligantions will be accepted in this study)
2. Between the ages of 21 and 65 years; and
3. A diagnosis of major depression (HDRS\>=15) and
4. A minimum of 25 mm on a VAS measure of painful symptoms (ranging from 0-100 mm), but no need for regular pain medication and HAMD-17 item 13 minimum rated as 1,
5. Medically and neurologically healthy on the basis of history, physical examination, EKG, screening laboratories (CBC w/ differential, TSH, Free-T4, ASAT, ALAT, GGT, BUN, creatinine, calcium, phosphorous, magnesium, total protein, albumin, electrolytes) and
6. Absence of substance abuse on the basis of history and urine toxicology at screening.

Exclusion Criteria

1. DSM-IV psychiatric and substance abuse diagnosis (excluding nicotine dependence) by history or psychiatric evaluation that includes a structured diagnostic interview for non-patient populations (SCID-NP)
2. Current suicide risk sufficient to preclude treatment on an outpatient base: Higher than "2" on the "suicide" item of HAMD-17, or history of suicide attempt(s) in the past 12 months, or who, in the investigator's judgment, poses a current suicidal or homicidal risk.
3. Clinical indications of organic brain disease, dementia, or cognitive impairment.
4. History of substance dependence other than nicotine and consumption within the last year
5. Any medical condition that would preclude the use of duloxetine treatment as

* A known hypersensitivity to duloxetine or any of the inactive ingredients.
* Intake of monoamine oxidase inhibitors (MAOIs) or suffering from uncontrolled narrow-angle glaucoma.
* Signs of any hepatic insufficiency
* Intake of inhibitors of CYP1A2 (as fluvoxamine, ciprofloxacin, enoxacin)
* End-stage renal disease (requiring dialysis) or severe renal impairment (estimated creatinine clearance \[CrCl\] \<30 mL/min)
6. Subnormal intellectual potential as assessed by the WST-IQ \[Metzler. und Schmidt, 1992\]

Minimum Eligible Age

21 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Wolfgang Maier, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

University of Bonn, Department of Psychiatry

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Clinic Bonn

Bonn, North Rhine-Westphalia, Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Christian G Schuetz, MD MPH

Role: CONTACT

Phone: +49 228 287 9664

Email: christian.schü[email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Christian G Schütz

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2006-001079-39

Identifier Type: -

Identifier Source: org_study_id